We have collected information about Smarticles Liposome Delivery Technology for you. Follow the links to find out details on Smarticles Liposome Delivery Technology.
https://www.in-pharmatechnologist.com/Article/2010/07/29/Marina-buys-Smarticles-liposomal-delivery-system
By screening close to 1,000 different Smarticles Novosom has identified variants that are stable, effective and can target the liver, inflamed sites or tumours. Preclinical tests suggest that Smarticles are safe and well tolerated. Novosom has applied the technology to the delivery of …
https://www.vaxxenlabs.com/what-is-liposomal-technology/
Choose Wisely: Choose Liposomal Delivery Technology. At this time, only a handful of nutritional supplement companies are relying on the benefits of liposomal delivery technology. It’s still a fairly new technology and isn’t widely available across all nutritional supplements and vitamins.
https://drug-dev.com/marina-biotech-strengthens-ip-estate-for-smarticles-nucleic-acid-delivery-technology/
The SMARTICLES platform allows us to pursue a number of amphoteric liposome structures with enhanced delivery properties. Our broad delivery technologies permit the development of formulations for both targeted delivery, including the use of certain peptide-based moieties, as well as delivery via multiple routes of administration, such as ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4664963/
Dec 01, 2015 · In this review, we will discuss the advances in liposome assisted drug delivery, biological challenges that still remain, and current clinical and experimental use of liposomes for biomedical applications. The translational obstacles of liposomal technology will also be presented.Author: Lisa Sercombe, Tejaswi Veerati, Tejaswi Veerati, Fatemeh Moheimani, Sherry Y. Wu, Anil K. Sood, Susa...
https://www.sciencedirect.com/science/article/pii/S0169409X12002980
The first closed bilayer phospholipid systems, called liposomes, were described in 1965 and soon were proposed as drug delivery systems. The pioneering work of countless liposome researchers over almost 5 decades led to the development of important technical advances such as remote drug loading, extrusion for homogeneous size, long-circulating (PEGylated) liposomes, triggered release liposomes ...Author: Theresa M. Allen, Pieter R. Cullis
https://en.wikipedia.org/wiki/Liposome
A liposome is a spherical vesicle having at least one lipid bilayer.The liposome can be used as a vehicle for administration of nutrients and pharmaceutical drugs. Liposomes can be prepared by disrupting biological membranes (such as by sonication).. Liposomes are most often composed of phospholipids, especially phosphatidylcholine, but may also include other lipids, such as egg ...
https://www.manufacturingchemist.com/news/article_page/Smarticles_aim_to_deliver/38950
Under the terms of the collaboration, ProNAi will license Novosom's Smarticles liposome technology for use in all human disease targeted by ProNAi's PNT100 drug candidate. The agreement comprises an upfront payment, milestone payments and royalties. ProNAi …
https://www.sciencedirect.com/science/article/pii/S0165614709001370
Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer. ... Nanoscale drug delivery systems using liposomes and nanoparticles are emerging technologies for the rational delivery of chemotherapeutic drugs in the treatment of cancer. ... Recent advances in liposome technology offer better treatment of multidrug-resistant ...Author: Yogeshkumar Malam, Marilena Loizidou, Alexander M. Seifalian, Alexander M. Seifalian
https://www.marketwatch.com/press-release/marina-biotech-expands-global-patent-protection-of-clinical-stage-nucleic-acid-delivery-technologies-2015-04-23
Apr 23, 2015 · The claims of Marina Biotech's patent for licensed SMARTICLES(R) delivery technology allowed in Japan (Japan Patent Application No. 2010-528325) cover delivery technologies based on …
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5363494/
Mar 17, 2017 · Mirna Therapeutics recently halted a phase 1 study of MRX34 because multiple immune-related severe adverse events (SAEs, grade 4) were observed in five patients dosed with the study drug.14 The reported cytokine release syndrome might be induced by Smarticles, a liposome delivery technology licensed by Marina Biotech.13, 15 Mirna Therapeutics ...Author: Yuanyu Huang, Yuanyu Huang
Searching for Smarticles Liposome Delivery Technology?
You can just click the links above. The data is collected for you.
